UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
SCHEDULE 14A
(Rule
14a-101)
INFORMATION
REQUIRED IN PROXY STATEMENT
SCHEDULE
14A INFORMATION
Proxy
Statement Pursuant to Section 14(a) of the Securities Exchange Act of
1934
(Amendment
No. )
Filed by
the Registrant x
Filed by
a Party other than the Registrant o
Check the
appropriate box:
o Preliminary
Proxy Statement
¨ Confidential,
for Use of the Commission Only (as permitted by Rule14a-6(e)(2))
o Definitive
Proxy Statement
x Definitive
Additional Materials
o Soliciting
Material Under Rule 14a-12
|
THE
QUIGLEY CORPORATION
|
|
(Name
of Registrant as Specified in Its Charter)
|
|
|
|
(Name
of Persons(s) Filing Proxy Statement, if Other Than the
Registrant)
|
Payment
of Filing Fee (Check the appropriate box):
x No
fee required.
¨ Fee
computed on table below per Exchange Act Rules 14a-6(i)(1) and
0-11.
(1) Title
of each class of securities to which transaction applies:
(2) Aggregate
number of securities to which transaction applies:
|
|
(3)
|
Per
unit price or other underlying value of transaction computed pursuant to
Exchange Act Rule 0-11 (set forth the amount on which the filing fee is
calculated and state how it was
determined):
|
(4) Proposed
maximum aggregate value of transaction:
(5) Total
fee paid:
¨ Fee
paid previously with preliminary materials:
¨ Check
box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2)
and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement
number, or the form or schedule and the date of its filing.
(1) Amount
previously paid:
(2) Form,
Schedule or Registration Statement No.:
(3) Filing
Party:
(4) Date
Filed:
On June
1, 2009, The Quigley Corporation issued the following press
release.
THE
QUIGLEY CORPORATION ANNOUNCES FINAL VOTING RESULTS FOR
2009
ANNUAL MEETING OF SHAREHOLDERS
Judge
Orders Incumbent Board to Remain In Place Until Further Hearing
Final
Outcome of Director Election Remains Uncertain
DOYLESTOWN, PA. – June 1, 2009 – The Quigley Corporation, (Nasdaq:
QGLY), www.quigleyco.com, today announced that IVS
Associates, Inc., the inspector of election for Quigley’s 2009 annual meeting of
shareholders, issued its final report, showing that Karkus’ seven director
nominees received a larger number of votes than Quigley’s incumbent
directors.
The
Company also announced that despite the final voting results issued today by
IVS, the final outcome of the director election remains uncertain. On
May 19, 2009, one day before the Company’s 2009 Annual Meeting, the Company
announced it had uncovered an undisclosed financial arrangement between Karkus
and the Company’s Quigley Pharma, Inc. subsidiary COO, Dr. Richard A.
Rosenbloom. Karkus had previously stated in sworn testimony that at
no time did he have any financial arrangement with any employee of The Quigley
Corporation. Since the Annual Meeting, the Company has learned that
Dr. Rosenbloom may have also had undisclosed financial arrangements with one of
Karkus’ director nominees and with John Ligums, an alleged member of the Karkus
Group.
On May
29, 2009, upon a motion by the Company detailing these recent developments, the
District Court Judge in the United States District Court for the Eastern
District of Pennsylvania ordered the Company to operate under a standstill
agreement with respect to the composition of the Company’s Board of Directors
pending a Court hearing on the motion. The Company expects the motion will be
heard by Friday, June 5, 2009.
About The Quigley
Corporation
The
Quigley Corporation (NASDAQ: QGLY, http://www.Quigleyco.com)
is a diversified natural health medical science company. Its
Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE®
family of lozenges, gums and sugar free tablets clinically proven to cut the
common cold nearly in half. COLD-EEZE customers include leading
national wholesalers and distributors, as well as independent and chain food,
drug and mass merchandise stores and pharmacies. The Quigley
Corporation has several wholly owned subsidiaries; Quigley Manufacturing Inc.
consists of two FDA approved facilities to manufacture COLD- EEZE® lozenges as
well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc.
(http://www.QuigleyPharma.com)
conducts research in order to develop and commercialize a pipeline of patented
botanical and naturally derived potential prescription drugs.
Forward-Looking
Statements
Certain
statements in this press release are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995 and involve
known and unknown risk, uncertainties and other factors that may cause the
Company's actual performance or achievements to be materially different from the
results, performance or achievements expressed or implied by the forward-looking
statement. Factors that impact such forward-looking statements include, among
others, changes in worldwide general economic conditions, changes in interest
rates, government regulations, and worldwide competition.
CONTACT:
|
Gerard M. Gleeson
The Quigley Corporation
Vice President, CFO
(215) 345-0919
|
Mark Harnett / Bob Marese
MacKenzie Partners, Inc.
(212) 929-5500
Quigley@mackenziepartners.com
|
Carl Hymans
G. S. Schwartz & Co.
212-725-4500
carlh@schwartz.com
|